Skip to content
Triangle logo TriangleGet started
← Study library

NCT05070247 · REGISTRY CONDITION SEARCH

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1, PHASE2
Status at capture
TERMINATED
Registry last update
2026-01-22

This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors. The aims of the study are: * to assess the safety profile of TAK-500 when given alone and when given with pembrolizumab. * to assess the anti-tumor effects of TAK-500, when given alone and when given with pembrolizumab, in adults with locally advanced or metastatic solid tumors. Participants may receive TAK-500 for up to 1 year. Participants may continue with their treatment if they have continuing benefit and if this is approved by their study doctor. Participants who are receiving TAK-500 either alone or with pembrolizumab will continue with their treatment until their disease progresses or until they or their study doctor decide they should stop this treatment.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Dose Escalation: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)

→

outcome · POSTED

Dose Escalation: Number of Participants With Grade 3 or Higher TEAEs

→

outcome · POSTED

Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs)

→

outcome · POSTED

Dose Escalation: Number of Participants Reporting One or More Treatment-emergent Serious Adverse Events (SAEs)

→

outcome · POSTED

Dose Escalation: Number of Participants With One or More TEAEs Leading to Dose Modifications and Treatment Discontinuations

→

outcome · POSTED

Dose Expansion: Overall Response Rate (ORR)

→

outcome · POSTED

Dose Escalation: Cmax: Maximum Serum Concentration for TAK-500

→

outcome · POSTED

Dose Escalation: Tmax: Time to Reach the Maximum Serum Concentration (Cmax) for TAK-500

→

outcome · POSTED

Dose Escalation: AUCt: Area Under the Serum Concentration-time Curve From Time 0 to Time t for TAK-500

→

outcome · POSTED

Dose Escalation: AUCinf: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for TAK-500

→

outcome · POSTED

Dose Escalation: t1/2: Terminal Disposition Phase Half-life for TAK-500

→

outcome · POSTED

Dose Escalation: CL: Total Clearance After Intravenous Administration for TAK-500

→

outcome · POSTED

Dose Escalation: Vss: Volume of Distribution at Steady State After Intravenous Administration for TAK-500

→

outcome · POSTED

Dose Escalation: Changes in Intratumoral Tumor Cell Infiltration

→

outcome · POSTED

Dose Escalation: Number of Participants With Positive Anti-drug Antibody (ADA) (Acquired Immunogenicity)

→

outcome · POSTED

Dose Escalation: Overall Response Rate (ORR)

→

outcome · POSTED

Dose Escalation: Disease Control Rate (DCR)

→

outcome · POSTED

Dose Escalation: Duration of Response (DOR)

→

outcome · POSTED

Dose Escalation: Time to Response (TTR)

→

outcome · POSTED

Dose Expansion: Progression Free Survival (PFS)

→

outcome · POSTED

Dose Expansion: Overall Survival (OS)

→

outcome · POSTED

Dose Expansion: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)

→

outcome · POSTED

Dose Expansion: Number of Participants With Grade 3 or Higher TEAEs

→

outcome · POSTED

Dose Expansion: Number of Participants With Dose Limiting Toxicities (DLTs)

→

outcome · POSTED

Dose Expansion: Number of Participants Reporting One or More Treatment-emergent SAEs

→

outcome · POSTED

Dose Expansion: Number of Participants With One or More TEAEs Leading to Dose Modifications and Treatment Discontinuations

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: 1. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1. 2. Individuals with the following pathologically confirmed (cytological diagnosis is adequate) select locally advanced or metastatic solid tumors, whose disease has progressed on or are intolerant to standard therapy: 1. Gastroesophageal (esophageal, gastroesophageal junction, and gastric) adenocarcinoma, pancreatic adenocarcinoma, hepatocellular carcinoma (HCC), nonsquamous non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), mesothelioma, triple-negative breast cancer (TNBC), renal clear cell carcinoma (RCC) and nasopharyngeal carcinoma (NPC). Participants who are intolerant to all standard therapies are those who have developed clinical or laboratory abnormalities that prevent continued drug administration as evaluated by the principal investigator at the time of screening. 2. For dose expansion in 2L nonsquamous NSCLC (TAK-500 plus pembrolizumab): * Participants with pathologically confirmed (cytological diagnosis is adequate) locally advanced or metastatic nonsquamous NSCLC. * Participants may not have a known targetable driver mutation, rearrangement or amplification (eg, EGFR, ALK, MET, ROS1, BRAF, KRASG12C, etc.). * Must have had disease progression while on or following 1 prior line of therapy: \- Disease progression while on or following at least 6 weeks of 1 prior anti-PD-(L)1 therapy in the recurrent locally advanced or metastatic setting. OR Disease progression/recurrence within 6 months of the completion of anti-PD-(L)1 therapy if administered in the adjuvant/neoadjuvant setting. Prior anti-PD-(L)1 therapy may have been given with or without an anti-CTLA4 antibody and/or chemotherapy (eg, carboplatin and pemetrexed). * Participants are eligible regardless of PD-L1 status. 3. For dose expansion in 3L nonsquamous NSCLC (TAK-500 SA): * Participants with pathologically confirmed (cytological diagnosis is adequate) locally advanced or metastatic nonsquamous NSCLC. * Participants may not have a known targetable driver mutation, rearrangement or amplification (eg, EGFR, ALK, MET, ROS1, BRAF, KRASG12C, etc.). * Must have had disease progression while on or following 2 prior lines of therapy: * Disease progression while on or following at least 6 weeks of 1 prior anti-PD-(L)1 therapy in the recurrent locally advanced or metastatic setting OR Disease progression/recurrence within 6 months of the completion of 1 prior anti-PD-(L)1 therapy if administered in the adjuvant/neoadjuvant setting. Prior anti-PD-(L)1 therapy may have been given with or without an anti-CTLA4 antibody and/or chemotherapy (eg, carboplatin and pemetrexed). * Participants must have had disease progression while on or after 1 or 2 lines of chemotherapy in the recurrent locally advanced or metastatic setting. If the anti-PD-(L)1 therapy is given in combination with chemotherapy, participant must have progressed on an additional line of chemotherapy. * Participants are eligible regardless of PD-L1 status. 4. For dose expansion in 2L pancreatic adenocarcinoma (TAK-500 SA and TAK-500 plus pembrolizumab): * Participants with pathologically confirmed (cytological diagnosis is adequate) locally advanced or metastatic pancreatic adenocarcinoma. * Must have had disease progression while on or following 1 prior line of therapy: \- One prior line of fluorouracil- or gemcitabine-based chemotherapy (eg, FOLFIRINOX, FOLFOX, FOLFIRI, gemcitabine/nab-paclitaxel) in the metastatic/recurrent locally advanced setting. Prior chemotherapy in the neoadjuvant/adjuvant setting does not qualify unless the participant had progression of disease within 6 months of completion of neoadjuvant/adjuvant chemotherapy. * Must not have had prior exposure to anti-PD-(L)1 therapy. * Participants with MSI-H/dMMR disease are not eligible. * Participants are eligible regardless of PD-L1 status. 5. For dose expansion in 3L RCC (TAK-500 plus pembrolizumab): * Participants with pathologically confirmed (cytological diagnosis is adequate) locally advanced or metastatic RCC. * Must have had disease progression while on or following 2 prior lines of therapy: * Disease progression while on or following at least 6 weeks of 1 prior anti-PD-(L)1 therapy in the recurrent locally advanced or metastatic setting. OR Disease progression/recurrence within 6 months of the completion of anti-PD-(L)1 therapy if administered in the adjuvant/neoadjuvant setting. Prior anti-PD-(L)1 therapy may have been given with or without an anti-CTLA4 antibody and/or an anti-VEGFR TKI. * Participants must have had prior therapy with 1 or 2 lines of VEGFR TKIs in the metastatic/recurrent locally advanced setting. If anti-PD-(L)1 therapy was given in combination with a VEGFR TKI, the participant must have had progressive disease on an additional line of therapy (eg, VEGFR TKI or VEGFR TKI-containing combination). * Participants are eligible regardless of PD-L1 status. 3. Must have at least 1 RECIST version 1.1 measurable lesion. Lesions in previously irradiated areas (or other local therapy) should not be selected as measurable/target lesions unless there has been demonstrated radiographic progression in that lesion. RECIST v1.1 target lesions must include at least 1 lesion that was not previously irradiated. 4. Adequate bone marrow, renal, and hepatic functions, as determined by the following laboratory parameters: 1. Absolute neutrophil count (ANC) greater than or equal to (\>=) 1000/ microliter (mcL), platelet count \>=75,000/mcL, and hemoglobin \>= 8.0 grams per deciliter (g/dL) without growth factor support for ANC or transfusion support 2. Total bilirubin \<=1.5 times the institutional upper limit of normal (ULN). For participants with Gilbert's disease or HCC, \<=3 milligrams per deciliter (mg/dL). 3. Serum alanine aminotransferase and aspartate aminotransferase \<=3.0\*ULN or \<=5.0\*ULN with liver metastases or HCC. 4. Albumin \>=3.0 g/dL. 5. Calculated creatinine clearance using the Cockcroft-Gault formula \>=30 mL/minute. 5. Left ventricular ejection fraction (LVEF) \>50%, as measured by echocardiogram or multiple gated acquisition scan (MUGA) within 4 weeks before receiving the first dose of study drug. 6. For participants with HCC only: Child-Pugh score less than or equal to 7 (Child-Pugh A or B7). 7. Clinically significant toxic effects of previous therapy have recovered to Grade 1 (per National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] Version 5.0) or baseline, except for alopecia, Grade 2 peripheral neuropathy, and/or autoimmune endocrinopathies with stable endocrine replacement therapy. 8. Participants previously treated with fully human/humanized antineoplastic monoclonal antibodies must not have received treatment with such antibodies for at least 4 weeks or the time period equal to the dosing interval, whichever is shorter. No washout period is required for prior treatment with pembrolizumab or other anti-programmed cell death protein 1 (PD-1) antibodies, although the first study dose of these drugs must not occur at an interval less than standard of care (that is, 3 weeks for 200 mg of IV pembrolizumab). Exclusion Criteria: 1. History of any of the following \<=6 months before first dose of study drug(s): congestive heart failure New York Heart Association Grade III or IV, unstable angina, myocardial infarction, persistent hypertension \>=160/100 millimeters of mercury (mmHg) despite optimal medical therapy, ongoing cardiac arrhythmias of Grade \>2 (including atrial flutter/ fibrillation or intermittent ventricular tachycardia), other ongoing serious cardiac conditions (example, Grade 3 pericardial effusion or Grade 3 restrictive cardiomyopathy), or symptomatic cerebrovascular events. Chronic, stable atrial fibrillation on stable anticoagulation therapy, including low molecular-weight heparin, is allowed. 2. QT interval with Fridericia correction method \>450 milliseconds (men) or \>475 milliseconds (women) on a 12- lead ECG during the screening period. 3. Grade \>=2 hypotension (that is, hypotension for which nonurgent intervention is required) at screening or during C1D1 predose assessment. 4. Oxygen saturation \<92% on room air at screening or during C1D1 predose assessment. 5. Treatment with other STING agonists/antagonists, Toll-like receptor agonists or CCR2 agonist/antagonist within the past 6 months. 6. Active diagnosis of pneumonitis, interstitial lung disease, severe chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, other restrictive lung diseases, acute pulmonary embolism, or Grade \>=2 pleural effusion not controlled by tap or requiring indwelling catheters. 7. Grade \>=2 fever of malignant origin. 8. Chronic, active hepatitis (example, participants with known hepatitis B surface antigen seropositive and/or detectable hepatitis C virus \[HCV\] RNA). 9. History of hepatic encephalopathy. 10. Prior or current clinically significant ascites, as measured by physical examination, that requires active paracentesis for control. 11. Treatment with any investigational products or other anticancer therapy (including chemotherapy, targeted agents, and immunotherapy), within 14 days or 5 half-lives, whichever is shorter, before C1D1 of study drug(s). 12. Radiation therapy within 14 days (42 days for radiation to the lungs) and/ or systemic treatment with radionuclides within 42 days before C1D1 of study drug(s). Participants with clinically relevant ongoing pulmonary complications from prior radiation therapy are not eligible. 13. Use of systemic corticosteroids or other immunosuppressive therapy, concurrently or within 14 days of C1D1 of study drug(s), with the following exceptions: * Topical, intranasal, inhaled, ocular, intra-articular, and/or other nonsystemic corticosteroids. * Physiological doses of replacement steroid therapy (example, for adrenal insufficiency), not to exceed the equivalent of 10 mg prednisone daily. 14. Recipients of allogeneic or autologous stem cell transplantation or organ transplantation. Additional criteria specific for participants in TAK-500 and pembrolizumab combination arm only: * Contraindication to the administration of a pembrolizumab or prior intolerance to pembrolizumab or other anti-PD-1 or anti-programmed cell death protein ligand 1 antibody. * History of intolerance to any component of the study treatment agents or known serious or severe hypersensitivity reaction to any of the study drugs or their excipients. (Pembrolizumab is formulated with L-histidine, polysorbate 80, and sucrose.
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Participants received TAK-500, 8 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle (once every 3 weeks, Q3W) for up to 1 year.
    intervention Names
    1. Drug: TAK-500
    label
    Single Agent Dose Escalation: TAK-500 8 µg/kg
    type
    EXPERIMENTAL
  2. description
    Participants received premedication with 8 mg/kg tocilizumab (TOCI) followed by TAK-500, 8 µg/kg IV infusion, once on Day 1 of each 21-day treatment cycle (Q3W) for up to 1 year.
    intervention Names
    1. Drug: TAK-500
    2. Drug: Tocilizumab
    label
    Single Agent Dose Escalation: TAK-500 8 µg/kg + 1 TOCI
    type
    EXPERIMENTAL
  3. description
    Participants received TAK-500, 16 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle (Q3W) for up to 1 year.
    intervention Names
    1. Drug: TAK-500
    label
    Single Agent Dose Escalation: TAK-500 16 µg/kg
    type
    EXPERIMENTAL
  4. description
    Participants received premedication with dexamethasone (DEX) as a single 10 mg IV bolus 1 hour before the administration of TAK-500, 16 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle (Q3W) for up to 1 year.
    intervention Names
    1. Drug: TAK-500
    2. Drug: Dexamethasone
    label
    Single Agent Dose Escalation: TAK-500 16 µg/kg + 1 DEX
    type
    EXPERIMENTAL
  5. description
    Participants received premedication with dexamethasone 10 mg tablets orally 12 hours prior and 10 mg IV bolus 1 hour before administration of TAK-500, 16 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle (Q3W) for up to 1 year.
    intervention Names
    1. Drug: TAK-500
    2. Drug: Dexamethasone
    label
    Single Agent Dose Escalation: TAK-500 16 µg/kg + 2 DEX
    type
    EXPERIMENTAL
  6. description
    Participants received premedication with 8 mg/kg tocilizumab followed by TAK-500, 16 µg/kg, IV infusion, intravenously, once on Day 1 of each 21-day treatment cycle, Q3W , for up to 1 year.
    intervention Names
    1. Drug: TAK-500
    2. Drug: Tocilizumab
    label
    Single Agent Dose Escalation: TAK-500 16 µg/kg + 1 TOCI
    type
    EXPERIMENTAL
  7. description
    Participants received premedication with dexamethasone 10 mg tablets orally 12 hours prior and 10 mg IV bolus 1 hour before administration of TAK-500, 24 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year.
    intervention Names
    1. Drug: TAK-500
    2. Drug: Dexamethasone
    label
    Single Agent Dose Escalation: TAK-500 24 µg/kg + 2 DEX
    type
    EXPERIMENTAL
  8. description
    Participants received premedication with 8 mg/kg tocilizumab followed by TAK-500, 24 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle, Q3W , for up to 1 year.
    intervention Names
    1. Drug: TAK-500
    2. Drug: Tocilizumab
    label
    Single Agent Dose Escalation: TAK-500 24 µg/kg + 1 TOCI
    type
    EXPERIMENTAL
  9. description
    Participants received premedication with dexamethasone 10 mg tablet orally 12 hours prior and 10 mg IV bolus 1 hour before administration of TAK-500, 40 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year.
    intervention Names
    1. Drug: TAK-500
    2. Drug: Dexamethasone
    label
    Single Agent Dose Escalation: TAK-500 40 µg/kg + 2 DEX
    type
    EXPERIMENTAL
  10. description
    Participants received premedication with dexamethasone 10 mg tablet orally 12 hours prior and 10 mg IV bolus 1 hour before administration of TAK-500, 60 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle, Q3W for up to 1 year.
    intervention Names
    1. Drug: TAK-500
    2. Drug: Dexamethasone
    label
    Single Agent Dose Escalation: TAK-500 60 µg/kg + 2 DEX
    type
    EXPERIMENTAL
  11. description
    Participants received premedication with 8 mg/kg tocilizumab followed by TAK-500, 8 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle Q3W , for up to 1 year, along with pembrolizumab 200 mg IV infusion, once on Day 1 of each 21-day treatment cycle or on Days 1 and 22 in a 42-day cycle (Q3W) for up to 1 year.
    intervention Names
    1. Drug: TAK-500
    2. Drug: Pembrolizumab
    3. Drug: Tocilizumab
    label
    Combination Dose Escalation: TAK-500 8 µg/kg + 1 TOCI + Pembrolizumab
    type
    EXPERIMENTAL
  12. description
    Participants received premedication with 8 mg/kg tocilizumab followed by TAK-500, 16 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle Q3W , for up to 1 year, along with pembrolizumab 200 mg IV infusion, once on Day 1 of each 21-day treatment cycle Q3W for up to 1 year.
    intervention Names
    1. Drug: TAK-500
    2. Drug: Pembrolizumab
    3. Drug: Tocilizumab
    label
    Combination Dose Escalation: TAK-500 16 µg/kg + Pembrolizumab + 1 TOCI
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Combination Dose Escalation: TAK 500 24 µg/kg + Pembrolizumab + 2 DEX
    2. Combination Dose Escalation: TAK-500 16 µg/kg + Pembrolizumab + 1 TOCI
    3. Combination Dose Escalation: TAK-500 40 µg/kg + Pembrolizumab + 2 DEX
    4. Combination Dose Escalation: TAK-500 8 µg/kg + 1 TOCI + Pembrolizumab
    5. Dose Expansion: TAK-500
    6. Single Agent Dose Escalation: TAK-500 16 µg/kg
    7. Single Agent Dose Escalation: TAK-500 16 µg/kg + 1 DEX
    8. Single Agent Dose Escalation: TAK-500 16 µg/kg + 1 TOCI
    9. Single Agent Dose Escalation: TAK-500 16 µg/kg + 2 DEX
    10. Single Agent Dose Escalation: TAK-500 24 µg/kg + 1 TOCI
    11. Single Agent Dose Escalation: TAK-500 24 µg/kg + 2 DEX
    12. Single Agent Dose Escalation: TAK-500 40 µg/kg + 2 DEX
    description
    TAK-500 IV infusion.
    name
    TAK-500
    type
    DRUG
  2. arm Group Labels
    1. Combination Dose Escalation: TAK 500 24 µg/kg + Pembrolizumab + 2 DEX
    2. Combination Dose Escalation: TAK-500 16 µg/kg + Pembrolizumab + 1 TOCI
    3. Combination Dose Escalation: TAK-500 40 µg/kg + Pembrolizumab + 2 DEX
    4. Combination Dose Escalation: TAK-500 8 µg/kg + 1 TOCI + Pembrolizumab
    description
    Pembrolizumab IV infusion.
    name
    Pembrolizumab
    type
    DRUG
  3. arm Group Labels
    1. Combination Dose Escalation: TAK-500 16 µg/kg + Pembrolizumab + 1 TOCI
    2. Combination Dose Escalation: TAK-500 8 µg/kg + 1 TOCI + Pembrolizumab
    3. Single Agent Dose Escalation: TAK-500 16 µg/kg + 1 TOCI
    4. Single Agent Dose Escalation: TAK-500 24 µg/kg + 1 TOCI
    5. Single Agent Dose Escalation: TAK-500 8 µg/kg + 1 TOCI
    description
    Tocilizumab IV infusion.
    name
    Tocilizumab
    type
    DRUG
  4. arm Group Labels
    1. Combination Dose Escalation: TAK 500 24 µg/kg + Pembrolizumab + 2 DEX
    2. Combination Dose Escalation: TAK-500 40 µg/kg + Pembrolizumab + 2 DEX
    3. Single Agent Dose Escalation: TAK-500 16 µg/kg + 1 DEX
    4. Single Agent Dose Escalation: TAK-500 16 µg/kg + 2 DEX
    5. Single Agent Dose Escalation: TAK-500 24 µg/kg + 2 DEX
    6. Single Agent Dose Escalation: TAK-500 40 µg/kg + 2 DEX
    7. Single Agent Dose Escalation: TAK-500 60 µg/kg + 2 DEX
    description
    Dexamethasone IV infusion.
    name
    Dexamethasone
    type
    DRUG
  5. arm Group Labels
    1. Combination Dose Escalation: TAK 500 24 µg/kg + Pembrolizumab + 2 DEX
    2. Combination Dose Escalation: TAK-500 40 µg/kg + Pembrolizumab + 2 DEX
    3. Single Agent Dose Escalation: TAK-500 16 µg/kg + 2 DEX
    4. Single Agent Dose Escalation: TAK-500 24 µg/kg + 2 DEX
    5. Single Agent Dose Escalation: TAK-500 40 µg/kg + 2 DEX
    6. Single Agent Dose Escalation: TAK-500 60 µg/kg + 2 DEX
    description
    Dexamethasone tablet.
    name
    Dexamethasone
    type
    DRUG
Study design
allocation
NON_RANDOMIZED
intervention Model
SEQUENTIAL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
61
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Adverse event (AE) means any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to the medicinal product. A TEAE was reported as an AE for which the date of onset was on or after the first dose of any study drug and on or before the 30 days after the last dose of any study drug (or 90 days after the last dose of study drug for immune-mediated AEs).
    measure
    Dose Escalation: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)
    time Frame
    Up to approximately 32.8 months
  2. description
    AE means any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to the medicinal product. A TEAE was reported as an AE for which the date of onset was on or after the first dose of any study drug and on or before the 30 days after the last dose of any study drug (or 90 days after the last dose of study drug for immune-mediated AEs). TEAE Grades was evaluated as per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.
    measure
    Dose Escalation: Number of Participants With Grade 3 or Higher TEAEs
    time Frame
    Up to approximately 32.8 months
  3. description
    DLT was defined as any of the TEAEs that occur during Cycle 1 and are considered by the investigator to be at least possibly related to TAK-500 as a SA or in combination with pembrolizumab. Toxicity will be evaluated according to NCI CTCAE version 5.0.
    measure
    Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs)
    time Frame
    Up to Cycle 1 (1 cycle = 21 days)
  4. description
    A TEAE is an AE for which the date of onset was on or after the first dose of any study drug and on or before 30 days after the last dose of any study drug (or 90 days after the last dose of study drug for immune-mediated AEs). Treatment-emergent SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event.
    measure
    Dose Escalation: Number of Participants Reporting One or More Treatment-emergent Serious Adverse Events (SAEs)
    time Frame
    Up to approximately 32.8 months
  5. description
    AE means any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to the medicinal product. A TEAE was reported as an AE for which the date of onset was on or after the first dose of any study drug and on or before the 30 days after the last dose of any study drug (or 90 days after the last dose of study drug for immune-mediated AEs).
    measure
    Dose Escalation: Number of Participants With One or More TEAEs Leading to Dose Modifications and Treatment Discontinuations
    time Frame
    Up to approximately 32.8 months
  6. description
    ORR is defined as the percentage of participants who achieve confirmed partial response (cPR) or confirmed complete response (cCR) (determined by the investigator) during the study in the response-evaluable population. ORR will be assessed as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. Complete response (CR): defined as disappearance of all target and non- target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than \<10 mm. Partial response (PR): defined as at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. cPR or cCR is defined as a PR or CR that is confirmed with additional imaging 6 weeks after initial response.
    measure
    Dose Expansion: Overall Response Rate (ORR)
    time Frame
    Up to approximately 32.8 months
secondary Outcomes
  1. measure
    Dose Escalation: Cmax: Maximum Serum Concentration for TAK-500
    time Frame
    Pre-infusion and multiple timepoints post-infusion from Day 1 to Day 15 of Cycles 1, 2, 3, 4, 9, and 15 (Cycle length=21 days)
  2. measure
    Dose Escalation: Tmax: Time to Reach the Maximum Serum Concentration (Cmax) for TAK-500
    time Frame
    Pre-infusion and multiple timepoints post-infusion from Day 1 to Day 15 of Cycles 1, 2, 3, 4, 9, and 15 (Cycle length=21 days)
  3. measure
    Dose Escalation: AUCt: Area Under the Serum Concentration-time Curve From Time 0 to Time t for TAK-500
    time Frame
    Pre-infusion and multiple timepoints post-infusion from Day 1 to Day 15 of Cycles 1, 2, 3, 4, 9, and 15 (Cycle length=21 days)
  4. measure
    Dose Escalation: AUCinf: Area Under the Serum Concentration-time Curve From Time 0 to Infinity for TAK-500
    time Frame
    Pre-infusion and multiple timepoints post-infusion from Day 1 to Day 15 of Cycles 1, 2, 3, 4, 9, and 15 (Cycle length=21 days)
  5. measure
    Dose Escalation: t1/2: Terminal Disposition Phase Half-life for TAK-500
    time Frame
    Pre-infusion and multiple timepoints post-infusion from Day 1 to Day 15 of Cycles 1, 2, 3, 4, 9, and 15 (Cycle length=21 days)
  6. measure
    Dose Escalation: CL: Total Clearance After Intravenous Administration for TAK-500
    time Frame
    Pre-infusion and multiple timepoints post-infusion from Day 1 to Day 15 of Cycles 1, 2, 3, 4, 9, and 15 (Cycle length=21 days)
  7. measure
    Dose Escalation: Vss: Volume of Distribution at Steady State After Intravenous Administration for TAK-500
    time Frame
    Pre-infusion and multiple timepoints post-infusion from Day 1 to Day 15 of Cycles 1, 2, 3, 4, 9, and 15 (Cycle length=21 days)
  8. description
    Measurement of changes in tumor immune cell infiltration were measured by immunohistochemistry on fresh tumor biopsies taken pre and post treatment (up to 23 days after first administration of TAK-500) for each participant.
    measure
    Dose Escalation: Changes in Intratumoral Tumor Cell Infiltration
    time Frame
    Up to 23 days after first administration of TAK-500
  9. description
    Number of participants with positive ADA at any scheduled post-baseline visit are reported.
    measure
    Dose Escalation: Number of Participants With Positive Anti-drug Antibody (ADA) (Acquired Immunogenicity)
    time Frame
    Up to approximately 32.8 months
  10. description
    ORR is defined as the percentage of participants who achieve cPR or cCR (determined by the investigator) during the study in the response-evaluable population. ORR will be assessed as per RECIST Version 1.1. CR: defined as disappearance of all target and non- target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than \<10 mm. PR: defined as at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. cPR or cCR is defined as a PR or CR that is confirmed with additional imaging 6 weeks after initial response.
    measure
    Dose Escalation: Overall Response Rate (ORR)
    time Frame
    Up to approximately 32.8 months
  11. description
    DCR is defined as the percentage of participants who achieve cCR + cPR + stable disease (SD) or better (determined by the investigator) greater than (\>) 6 weeks during the study in the response-evaluable population. DCR will be assessed as per RECIST Version 1.1. CR: disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD). PD: at least a 20% increase in the sum of diameters of target lesions.
    measure
    Dose Escalation: Disease Control Rate (DCR)
    time Frame
    Up to approximately 32.8 months
  12. description
    DOR is defined as the time from the date of first documentation of a cPR or better to the date of first documentation of PD for responders (cPR or better). Responders without documentation of PD will be censored at the date of last response assessment that is SD or better. DOR will be assessed as per RECIST Version 1.1. PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD). PD: at least a 20% increase in the sum of diameters of target lesions.
    measure
    Dose Escalation: Duration of Response (DOR)
    time Frame
    Up to approximately 32.8 months
Full study description
brief Summary
This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors. The aims of the study are: * to assess the safety profile of TAK-500 when given alone and when given with pembrolizumab. * to assess the anti-tumor effects of TAK-500, when given alone and when given with pembrolizumab, in adults with locally advanced or metastatic solid tumors. Participants may receive TAK-500 for up to 1 year. Participants may continue with their treatment if they have continuing benefit and if this is approved by their study doctor. Participants who are receiving TAK-500 either alone or with pembrolizumab will continue with their treatment until their disease progresses or until they or their study doctor decide they should stop this treatment.
detailed Description
The drug being tested in this study is called TAK-500. The study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of TAK-500 when used as a single agent (SA) and in combination with pembrolizumab in participants with locally advanced or metastatic solid tumors. The study will be conducted in 2 phases: Dose Escalation and Dose Expansion Phase. The study will enroll approximately 313 participants (approximately 82 in the Dose Escalation Phase and approximately 231 in Dose Expansion Phase). The dose escalation phase will determine the recommended dose of TAK-500 along with the combination agents for the dose expansion phase. All the participants will be assigned to one of the 9 arms: * Dose Escalation: TAK-500 Single Agent (SA) * Dose Escalation: TAK-500 + Pembrolizumab * Dose Expansion: 2L NSCLC: TAK-500 recommended dose 1 for expansion (RDE 1) + Pembrolizumab * Dose Expansion: 2L NSCLC: TAK-500 recommended dose 2 for expansion (RDE 2) + Pembrolizumab * Dose Expansion: 3L NSCLC: TAK-500 (RDE 1) SA * Dose Expansion: 3L NSCLC: TAK-500 (RDE 2) SA * Dose Expansion: 2L Pancreatic Adenocarcinoma: TAK-500 (RDE 1) + Pembrolizumab * Dose Expansion: 2L Pancreatic Adeno: TAK-500 (RDE 1) SA * Dose Expansion: 3L RCC: TAK-500 (RDE 1) + Pembrolizumab This multi-center trial will be conducted globally. Participants with demonstrated clinical benefit may continue treatment beyond 1 year if approved by the sponsor.
Source references
see Also Links
  1. label
    To obtain more information on the study, click here/on this link
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-9706b431f15fe9418c6d
      requested nct id
      NCT05070247
      primary nct id
      NCT05070247
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      0a018dbf1aa46f57978b6d16aa19b94d76d6d65cf1e297e889c8e599fef1fab1
      payload sha256
      fcb003b44baad92ba36ac3d06144dc1b84029e3ec7819c28dc16ec585d43db26
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-9706b431f15fe9418c6d
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT05070247
      occurrences
      1. context exact
        NCT05070247
        end
        11
        exact text
        NCT05070247
        start
        0
      offset unit
      unicode_code_points
      query cond
      Malignant Mesothelioma
      query disease state id
      ds-malignant-mesothelioma
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-malignant-mesothelioma-000.json
      source file sha256
      0a018dbf1aa46f57978b6d16aa19b94d76d6d65cf1e297e889c8e599fef1fab1
      source json pointer
      /studies/103/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      be1518e783a14fd7248f1240a5065e9e444e4852b1a0accee615e7166d9a5711

    Preserved source evidence · Not medical advice